Nuveen
CAPR icon

Nuveen’s Capricor Therapeutics CAPR Stock Holding History

Nuveen’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7M Buy
236,612
+73,706
+45% +$2.23M ﹤0.01% 2027
2026
Q1 		$4.95M Buy
162,906
+71,955
+79% +$1.92M ﹤0.01% 1886
2025
Q4 		$2.62M Buy
90,951
+1,878
+2% +$24.5K ﹤0.01% 2175
2025
Q3 		$642K Hold
89,073
– – ﹤0.01% 2810
2025
Q2 		$884K Sell
89,073
-68
-0.1% -$718 ﹤0.01% 2666
2025
Q1 		$846K Sell
89,141
-79,970
-47% -$1.11M ﹤0.01% 2708
2024
Q4 		$2.33M Buy
169,111
+134,791
+393% +$2.36M ﹤0.01% 2322
2024
Q3 		$522K Hold
34,320
– – ﹤0.01% 3005
2024
Q2 		$164K Buy
+34,320
New +$191K ﹤0.01% 3255

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen's CAPR Position: Q2 2026 in Review

Nuveen increased its Capricor Therapeutics (CAPR) stake by 45% in Q2 2026, buying an estimated $2.23M and bringing the position to 236,612 shares worth $5.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Nuveen first reported a position in CAPR in Q2 2024 and has held it in 9 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Nuveen held 236,612 shares of Capricor Therapeutics worth $5.7M as of Q2 2026.
  • Nuveen bought 73,706 Capricor Therapeutics shares in Q2 2026, an estimated $2.23M.
  • Capricor Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2027 holding.
  • Nuveen first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.